PRINTABLE VERSIONPRINTABLE VERSION EMAILEMAIL
Frost & Sullivan Applauds HDH Medical’s Visionary Management Team for Establishing the Company as a Viable Brand

London, UK - 22nd October 2007 - Frost & Sullivan has selected HDH Medical Ltd. as the recipient of the 2007 European Frost & Sullivan Award for Entrepreneurial Company of the Year in the vascular device market. A medical device start-up, the company has put together an experienced management team to complement its strong product offering and proven operational capabilities.

Hermetic Docking Head (HDH) vascular device, HDH Medical’s flagship product, enables suture-less open surgical and laparoscopic vascular procedures. These HDH procedures help surgeons to perform sutureless and leak-proof anastomosis in less than ten minutes. This shortens the cross-clamping time as well as operative and post-operative complications, restoring unrestricted blood flow to vital organs and tissues. The HDH device is leak-proof, migration free, and helps achieve permanent anastomosis through a simplified graft implantation procedure. Importantly, it is compatible with any standard vascular graft.

Significantly, the HDH technology enables open and laparoscopic repair of abdominal aortic aneurysms (AAA), aorto-iliac aneurysms and vascular occlusions. It has shown ability to shorten and facilitate these hitherto lengthy and technically complicated laparoscopic vascular repair procedures. “Laparoscopic aneurysm repair is expected to score over and largely replace the expensive, frequently complicated, and technically complex endovascular repair procedure,” says Frost & Sullivan Research Associate Sabita Ramachandran. “These benefits are likely to reduce mortality rate, shorten hospitalisation and ICU time, and lower procedure costs.”

HDH Medical Ltd has submitted three patents to protect intellectual property rights (IPR) for the device, the operative methods and the accessories, and is developing additional patents to protect overall IPR for the company. HDH Medical, Ltd. expects to receive Food and Drug Administration (FDA) approval in a year through the 510K, or “Fast Track”, route in the United States as a class II medical device. It could also obtain European approval (CE mark) in six months, once it conducts up to 10 human clinical trials. The product is classified as Class III for the use in central circulatory system and as Class IIb for the peripheral blood vessels.

“The primary target market segment for the device is open AAA and aorto-iliac aneurysms repair” notes Sabita Ramachandran. “The HDH device with a standard graft shortens time in surgery, lowers operative and post-operative complications, and requires fewer blood transfusions for open repair.”

Each year Frost & Sullivan presents this award to the small company that demonstrated superior entrepreneurial ability in its industry during the research period. This award signifies the company's identification of a unique and revolutionary product solution with significant market potential. It certifies that the company's marketing strategy is sound and poised for success.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About HDH Medical Ltd.

HDH Medical Ltd. was founded in November 2003 as an Israeli medical device start-up under the auspices of the Israeli Ministry of Trade and Industry within the framework of Yozmot HaEmek, a technological incubator located in Migdal HaEmek, Israel. HDH Medical Ltd. has a capable, experienced, multi-disciplinary and dedicated management team and makes extensive use of qualified sub-contractors. The members of the Scientific Advisory Team at HDH Medical Ltd, especially Dr. Boris Yoffe (Israel) and Prof. Inge Fourneau (Belgium), have professional expertise in the medical field. Their wide and varied experience helps HDH Medical Ltd to establish a strong base in their market of choice.
For more information visit www.hdhmedical.com or contact Irina Vaysbeyn, CEO, at irina@hdhmedical.com


About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit www.awards.frost.com.


Contact:

Stacie Jones
210.247.2450
Stacie.jones@frost.com

BACK TO TOP BACK TO TOP

QUICK SEARCH

GO GO
ADVANCED SEARCH
Search our research by date, market, technology, region or keywords
GO GO
SHARE
ANALYST BRIEFINGS
Attend our complementary interactive analyst briefings
VIEW LIST  VIEW LIST
PRESS RELEASE MAILING LIST
To receive industry breaking news and analysis sign up for our mailing list. Include your full contact details and specify your industry of interest.
URGENT INQUIRIES
We recognize journalist deadlines and will strive to meet your needs as quickly as possible
CONTACT US   CONTACT US
Sitemap | Disclaimer | Privacy
© Frost & Sullivan
Conseq